BioCentury on BioBusiness,
Finance
Regeneron hit on positive data for Ophthotech's Fovista in wet AMD
Related tables, figures and sidebars
Fovista proves eye catching
By Stacy Lawrence
Senior Writer
Published on
Monday, June 18, 2012
Regeneron Pharmaceuticals
Inc. (NASDAQ:REGN) lost $1.5 billion
in market cap last Wednesday as investors showed the first signs of doubt about
Eylea aflibercept's competitive position in the market for wet age-related
macular degeneration drugs. The trigger for the selloff was positive Phase IIb
AMD data from Ophthotech Corp. that ultimately could give an edge to
Regeneron competitor Roche (SIX:ROG; OTCQX:RHHBY).
Ophthotech tested its Fovista
in combination with Roche's Lucentis ranibizumab. The once-monthly combination
met the
75
words displayed of
375
words total.
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2013 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement and the BioCentury Terms of Use. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions at www.biocentury.com. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
|
Current Subscribers
If you are a current subscriber, log in below or in the upper right corner of this
page.
Log In
Subscription Option
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thank You
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
records.
close [ X ]